In a surprising turn of events, Apple has ceased the sale of its Apple Watch Series 9 and Ultra 2 in the United States due to an ongoing legal clash with health tech company Masimo. The conflict revolves around the blood oxygen detection feature, leading to a prohibition order by the US International Trade Commission (USITC). Here’s a breakdown of the situation:
Legal Battle and Decision Timeline
The USITC, responsible for trade-related mandates, issued a ban on importing the Series 9 and Ultra 2. This decision, stemming from a judge’s ruling in January that Apple infringed on Masimo patents, became final on Dec. 26 after the US Trade Representative’s review. Apple responded, expressing disagreement and pledging to explore all avenues to restore sales.
Impact on Apple’s Business
Apple’s Watch, a key product, has significantly contributed to its wearables, home, and accessories business. The size of its wearables unit alone matches that of a Fortune 150 company. The sales pause, initiated on Dec. 21 online and Dec. 24 in-store, specifically affects the Series 9 and Ultra 2 sold through Apple in the US.
Current Sales Landscape
While Apple has temporarily halted sales, the affected watches are still available on Best Buy, Amazon, Walmart, and Target’s websites. However, this situation may be short-lived as the order prohibits Apple from importing and selling to resellers.
The Legal Path Forward
Apple has appealed to the Federal Circuit and submitted a proposed redesign for US Customs approval. The customs office will decide on Jan. 12 whether the redesign infringes on Masimo’s patents, potentially paving the way for a resolution.
Alternatives and Recommendations
For those seeking alternatives, the Apple Watch SE remains unaffected and available. Additionally, Fitbit Versa 4 and Garmin Venu 3 offer cross-platform compatibility. Individuals keen on blood oxygen monitoring at home might consider standalone pulse oximeters, given the potential limitations of consumer wearables.
As the situation develops, stay tuned for updates on Apple’s efforts to resume sales and potential workarounds to the legal constraints.
